Key result
Specific phospholipase C (PLC) isozymes may potentially serve as important targets for the attenuation of cardiac hypertrophy in vulnerable patient populations at risk for heart failure.
Specific phospholipase C isozymes may serve as therapeutic targets to attenuate cardiac hypertrophy in patients at risk for heart failure.
protein-adenylyl cyclase signal transduction mechanisms in the early stages of cardiac hypertrophy development, but may become more relevant at the late stage of cardiac hypertrophy. From the information provided here, it is suggested that some specific PLC isozymes may potentially serve as important targets for the attenuation of cardiac hypertrophy in the vulnerable patient population at-risk for heart failure.
No takes yet. Share an insight, caveat, or question.
Tappia et al. (2022) conducted a review in Cardiac hypertrophy. Phospholipase C (PLC) isozymes targeting was evaluated. Specific phospholipase C (PLC) isozymes may potentially serve as important targets for the attenuation of cardiac hypertrophy in vulnerable patient populations at risk for heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: